Does Insurance Cover GLP-1s for Weight Loss? The BMI Math and the Prior-Auth Reality

The most common question about GLP-1s is also the most commonly mis-answered: does insurance cover them? People want a yes or no. The real answer is a gate sequence, and you can be denied at any gate for reasons that have nothing to do with whether the drug would help you. Understanding the gates is the difference between "my insurance won't cover it" (usually false) and "I didn't clear gate three" (usually the truth).

Here's the sequence, in the order the gates actually come.

Gate 1: Which indication is your prescription written for?

This is the gate that quietly decides everything downstream. The same molecule is sold under different brands for different approved uses:

• Semaglutide is Ozempic (type 2 diabetes) and Wegovy (weight loss/obesity).
• Tirzepatide is Mounjaro (type 2 diabetes) and Zepbound (weight loss/obesity).

Plans routinely cover the diabetes versions and exclude the weight-loss versions — or cover weight loss only under strict conditions. So the first thing that determines your coverage isn't your body or your need; it's which brand, for which indication, your prescription names. A person with diabetes and a person seeking weight loss can be prescribed the identical molecule and get opposite coverage answers.

The full molecule-to-brand-to-indication map is here — it's worth getting straight before you call your insurer, because the words you use on that call ("Wegovy" vs "Ozempic") change the answer.

Gate 2: The BMI threshold

For the weight-loss indication, plans that cover it almost always require a body-mass-index threshold that mirrors the drugs' FDA labels:

• BMI of 30 or higher (obesity), or
• BMI of 27 or higher with at least one weight-related condition — high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, and similar.

That "27-plus-a-comorbidity" branch is the one people miss. If your BMI is 27–29 and you assume you don't qualify, you may — if you have a qualifying condition documented in your chart. The word documented is doing work there: the comorbidity has to be in the record your prescriber submits, not just something you mention.

Gate 3: Prior authorization (and the first denial that isn't really a denial)

Even when your plan covers the drug and you clear the BMI gate, you usually hit prior authorization — the plan requires your prescriber to submit clinical justification before it will pay. This is where most people stall, because two things happen that feel like a wall but aren't:

• The first PA is frequently denied, sometimes for a missing box or a documentation gap rather than a real "no." A denial is the start of the process for a lot of approved-in-principle patients, not the end.
• Step therapy may require you to have tried (and failed) a cheaper option first — an older weight-loss drug, or lifestyle programs — before the plan will approve the GLP-1. If you haven't, the PA bounces until that history exists or is documented.

The practical move: when a PA is denied, get the specific reason in writing. "Denied" is not a reason; "BMI not documented" or "step therapy not met" is, and each has a different fix. A denial with a fixable reason is an appeal waiting to be won, not a closed door.

Gate 4: The appeal

If the drug is covered by your plan in principle but the PA keeps getting denied, you appeal — and for commercial plans this is often winnable, because many first denials are documentation problems, not coverage decisions. Your prescriber's office usually drives this, but you should confirm they've addressed the stated denial reason rather than resubmitting the same packet.

(Medicare is a different world entirely — Part D generally doesn't cover GLP-1s prescribed purely for weight loss at all, and the appeal rules there run on their own strict clock. If you're on Medicare, the coverage question and the appeal process are both different from the commercial-insurance version described here.)

What to do, in order

1. Confirm the indication on your prescription. Weight-loss brand or diabetes brand — this sets the whole path.
2. Check the BMI gate, including the 27-plus-comorbidity branch. Make sure any qualifying condition is documented, not just mentioned.
3. Expect a prior authorization, and expect the first one to possibly bounce. Get the specific denial reason in writing.
4. Fix the stated reason and appeal. Most winnable denials die on documentation, not on the merits.
5. If none of that works, price the self-pay route — manufacturer cash programs dropped substantially in 2025–2026, and the gap between "covered" and "self-pay" is smaller than it used to be.

The honest headline is that "does insurance cover GLP-1s" has no yes/no answer, and treating a prior-auth denial as a final no is the most expensive mistake in the sequence. Most people who "can't get it covered" actually stopped at a gate that had a key. The gates are annoying, they're real, and they're mostly passable if you know which one you're standing at.

I keep the current coverage-by-plan details and the PA-and-appeal specifics here, and a plain-language explainer of how GLP-1 pricing and coverage fit together here.

Coverage rules, BMI criteria, and program details verified July 2026. Plans vary; this is general information, not insurance or medical advice. Confirm specifics with your plan and prescriber.